Ginkgo Bioworks (NYSE:DNA) & ZIVO Bioscience (NASDAQ:ZIVO) Head-To-Head Review

ZIVO Bioscience (NASDAQ:ZIVO) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Valuation & Earnings

This table compares ZIVO Bioscience and Ginkgo Bioworks”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15,850.00	4,620.38	-$7.78 million	($4.88)	-4.05
Ginkgo Bioworks	$217.11 million	3.26	-$892.87 million	($13.08)	-0.94

ZIVO Bioscience has higher earnings, but lower revenue than Ginkgo Bioworks. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for ZIVO Bioscience and Ginkgo Bioworks, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0	1	0	0	2.00
Ginkgo Bioworks	3	1	1	0	1.60

Ginkgo Bioworks has a consensus price target of $4.58, indicating a potential downside of 62.84%. Given Ginkgo Bioworks’ higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than ZIVO Bioscience.

Volatility and Risk

ZIVO Bioscience has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

Profitability

This table compares ZIVO Bioscience and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Ginkgo Bioworks	-298.78%	-58.54%	-34.24%

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.